Ithaca Energy to Buy Remaining Stake in Cambo Field From Shell
By Anthony O. Goriainoff
Ithaca Energy said it has agreed to buy the remaining 30% stake in the Cambo field from Shell U.K., taking its stake to 100%, subject to fiscal conditions.
The London-listed oil-and-gas company said Tuesday that the acquisition has minimal near-term cost exposure, and will give it full control over Cambo's future development.
The company said in May that it had entered into the option to acquire the stake at a value equating to $1.50 per barrel of oil equivalent of the resource volume reference, upon certain conditions.
The Cambo field is the second-largest undeveloped oil and gas discovery in the North Sea, and is located north west of the Shetland Islands.
"We are pleased to conclude the marketing process with Shell and to take full ownership of the Cambo development... We believe that Cambo has an important role to play in providing energy security and economic benefit to the U.K., while reducing overall emissions intensity," Chief Executive Alan Bruce said.
Shares at 0740 GMT were down 1.40 pence, or 0.9%, at 147.60 pence.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 12, 2023 04:11 ET (08:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks